Sh Pharma (601607.SH) announced that its subsidiary Tianjin Xinyi Jingjing Pharmaceutical Co., Ltd. Recently received the Approval Notice for the Listing Application for chemical raw materials issued by the State Drug Administration (Notice No. 2024YS00123).
Sh Pharma announced that its subsidiary Tianjin Xinyi Jingjing Pharmaceutical Co., Ltd.'s hydrocortisone active pharmaceutical ingredient received the Approval Notice for the Listing Application for chemical raw materials issued by the State Drug Administration (Notice No. 2024YS00123), which has been approved for production.
Hydrocortisone is mainly used for the replacement treatment of adrenal cortical hypofunction and the treatment of congenital adrenal hyperplasia. The Approval Notice for Chemical Raw Materials Market Application (Notice No. 2024YS00123) has been issued by the National Medical Products Administration of China (NMPA) for the raw material, indicating that it meets the relevant regulations for domestic drug registration and can be sold in the domestic market. This has also provided valuable experience for the company's subsequent products in applying for raw materials. Please use your Futubull account to access the feature.